Protagonist Therapeutics(PTGX.US)与武田(Takeda)3期研究VERIFY初步结果积极助力PV患者摆脱放血治疗_老虎社区_美港股上老虎

Protagonist Therapeutics(PTGX.US)与武田(Takeda)3期研究VERIFY初步结果积极助力PV患者摆脱放血治疗

智通财经2025-03-04

智通财经APP获悉，Protagonist Therapeutics(PTGX.US)与武田(Takeda)今天宣布了3期研究VERIFY的初步积极结果。分析显示，该研究达到主要终点以及所有四个关键次要终点，其潜在“first-in-class”疗法rusfertide作为标准治疗的附加方案，使得近80%真性红细胞增多症(PV)患者不再需要接受放血治疗。PV患者发生致命性心血管事件和血栓形成的风险...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2516676946?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-04 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516676946","market":"sh","top_or_hot":-1,"title":"Protagonist Therapeutics(PTGX.US)与武田(Takeda)3期研究VERIFY初步结果积极 助力PV患者摆脱放血治疗","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，Protagonist Therapeutics(PTGX.US)与武田(Takeda)今天宣布了3期研究VERIFY的初步积极结果。分析显示，该研究达到主要终点以及所有四个关键次要终点，其潜在“first-in-class”疗法rusfertide作为标准治疗的附加方案，使得近80%真性红细胞增多症(PV)患者不再需要接受放血治疗。PV患者发生致命性心血管事件和血栓形成的风险...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1257725.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Protagonist Therapeutics(PTGX.US)与武田(Takeda)3期研究VERIFY初步结果积极 助力PV患者摆脱放血治疗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProtagonist Therapeutics(PTGX.US)与武田(Takeda)3期研究VERIFY初步结果积极 助力PV患者摆脱放血治疗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-04 21:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1257725.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，Protagonist Therapeutics(PTGX.US)与武田(Takeda)今天宣布了3期研究VERIFY的初步积极结果。分析显示，该研究达到主要终点以及所有四个关键次要终点，其潜在“first-in-class”疗法rusfertide作为标准治疗的附加方案，使得近80%真性红细胞增多症(PV)患者不再需要接受放血治疗。PV患者发生致命性心血管事件和血栓形成的风险...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1257725.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1257725.html","article_id":"2516676946","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516676946","pubTimestamp":1741093579,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，Protagonist Therapeutics与武田今天宣布了3期研究VERIFY的初步积极结果。PV患者发生致命性心血管事件和血栓形成的风险增加。当前治疗指南建议，将血容量降低至45%以下是PV患者的主要治疗目标。在20至32周期间，rusfertide治疗组的临床应答率为77%，显著高于安慰剂组的33%，试验主要终点定义为患者无需接受放血治疗。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","PTGX":"Protagonist Therapeutics Inc"},"translate_title":"Preliminary results of Protagonist Therapeutics (PTGX.US) and Takeda's Phase 3 study VERIFY actively help PV patients get rid of bloodletting treatment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTGX":1,"LENZ":1},"content_text":"智通财经APP获悉，Protagonist Therapeutics(PTGX.US)与武田(Takeda)今天宣布了3期研究VERIFY的初步积极结果。分析显示，该研究达到主要终点以及所有四个关键次要终点，其潜在“first-in-class”疗法rusfertide作为标准治疗的附加方案，使得近80%真性红细胞增多症(PV)患者不再需要接受放血治疗。PV患者发生致命性心血管事件和血栓形成的风险增加。许多PV患者需要定期接受放血治疗，通过移除血液来控制因红细胞过多而引起的血容量升高，同时还需接受细胞减少疗法。定期放血治疗可能会给患者带来治疗负担，并加剧包括严重疲劳、视力障碍和缺铁在内的症状，进而影响患者的生活质量。当前治疗指南建议，将血容量降低至45%以下是PV患者的主要治疗目标。分析显示，研究达成主要终点。在20至32周期间，rusfertide治疗组的临床应答率为77%，显著高于安慰剂组的33%(p<0.0001)，试验主要终点定义为患者无需接受放血治疗。此外，试验亦达成首个关键次要终点(即欧盟监管机构预设的主要终点)。在0至32周期间，rusfertide组患者的平均放血次数为0.5次，而安慰剂组为1.8次(p<0.0001)。而在另外三个预设的关键次要终点，包括血容量控制以及疲劳评估指标等结果，也均达到了统计学显著性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}